Screener
Myriad Genetics MYGN Q2 2026 earnings
Reported July 30, 2026 · After market close
Revenue$190.7MMiss by $15.3M
EPS-$0.25Miss by $0.19
Revenue estimate$206.0M
EPS estimate-$0.06
“During the quarter, we advanced work on a strategic review with the intention to identify initiatives to increase growth, profitability, and liquidity. We have activated an initiative called Ascend to increase organizational efficiency, effectivity and scalability and are being supported by a leading professional services firm. We are also doing a rigorous evaluation of our product portfolio to determine the optimal allocation of capital and enhancement of shareholder value.”
Next report
Nov 2, 2026 (in a month)Revenue estimate$191.4M
EPS estimate-$0.16
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Myriad Genetics report Q2 2026 earnings?
- Myriad Genetics (MYGN) reported Q2 2026 earnings on July 30, 2026 after market close.
- What were Myriad Genetics's Q2 2026 revenue and EPS?
- Myriad Genetics reported revenue of $190.7M and eps of $-0.25 for Q2 2026.
- Did Myriad Genetics beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $206.0M by $15.3M. EPS missed the consensus estimate of $-0.06 by $0.19.
- How did Myriad Genetics's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 10.5% from $213.1M a year earlier.
- Where can I find Myriad Genetics's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0000899923-26-000070) and the 10-Q periodic report (0000899923-26-000072) directly on SEC EDGAR. The filing index links above go to sec.gov.
